Archive: Ablating CAR T Cells for AML with Alemtuzumab: CIPO2015

417 views · Published 16 October 2015 · 15:49 · Indexed 28 October 2026

Channel: UW Video · 2015 · Education

Watch on YouTube

Dr. Sarah K. Tasian of The Children’s Hospital of Philadelphia speaks at the 4th International Conference on Immunotherapy in Pediatric Oncology (CIPO2015), hosted by Seattle Children’s Research Institute. 

Dr. Tasian discusses how long-term persistence of acute myeloid leukemia (AML) antigen-redirected chimeric antigen receptor T cells may lead to undesirable on target/off tumor toxicity. She explains how the development of effective T cell termination strategies may increase the potential therapeutic window of CAR T cell immunotherapy for patients with AML.

Sarah K. Tasian, MD, Assistant Professor of Pediatrics, Division of Oncology, The Children’s Hospital of Philadelphia 

09/26/2015

http://www.seattlechildrens.org/research/  AND 

http://www.seattlechildrens.org/research/childhood-cancer/CIPO-2015/

http://uwtv.org
The University of Washington is committed to ensuring digital accessibility in our services, programs, and activities. If you encounter accessibility barriers using videos found on this channel, please contact UW Video at uwvideo [at] uw [dot] edu.

More from this channel